Abstract 646P
Background
AVA6000 is a peptide drug conjugate, in which doxorubicin (dox) is bound by a linker that is specifically cleaved by FAP, which is overexpressed in the TME of many solid tumors.
Methods
The safety, pharmacokinetics (PK) and preliminary efficacy of AVA6000 was studied in a first-in-human, multicenter dose escalation phase I trial. AVA6000 was administered i.v. q3w or q2w using a 3+3 design in patients with locally advanced or metastatic solid tumors categorized as high or middle range FAP (FAPhigh and FAPmid) based on published data. AUC based dosing was used to calculate maximum safe number of cycles of AVA6000 (equivalent to cumulative dox dose of 550mg/m2).
Results
48 pts (median age 60 yr, range 30-79), median 3 prior therapy lines (range, 0-7) received AVA6000 doses of 80 to 385mg/m2 i.v. q3w, and a starting dose of 160mg/m2 given q2w. The safety profile was favorable with both schedules, the most frequent grade 3-4 hematologic toxicities were neutropenia (11%), anemia (6%), and thrombocytopenia (5%). Grade 3 non-hematologic toxicities included mucositis, fatigue and hematemesis (n=1). Two DLTs in the q3w arm were grade 2 cardiac failure (120mg/m2) and grade 4 neutropenia/thrombocytopenia (200mg/m2). Compared to conventional dox, PK showed reduced systemic exposure (AUC, 5-77%) and peak concentration (Cmax, 78-93%), without accumulation suggesting q2w dosing may be optimal. The therapeutic index of free dox was significantly increased, with respect to severe neutropenia, AUC and efficacy. No dose-response relationship was seen between troponin levels and AVA6000 dose. Concentrations of free dox in tumor biopsies (n=11) were ∼2 log scale higher than plasma. PK/PD modeling suggested free dox generation in the TME with an increased plasma distribution half-life. Two PR (RECISTv.1.1) and 3 minor responses (-10 to -29%) were observed in 5 pts with FAPhigh tumor types including salivary gland cancer and soft tissue sarcoma.
Conclusions
AVA6000 delivers high concentration of free dox to the TME relative to plasma, resulting in antitumor activity in FAPhigh tumor types with reduced systemic dox exposure, resulting in lower toxicity versus conventional dox.
Clinical trial identification
NCT04969835.
Editorial acknowledgement
Legal entity responsible for the study
Avacta Group Plc.
Funding
Avacta Group Plc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
731P - Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presenter: Mansoor Raza Mirza
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01